Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Blucora, Inc. stock logo
BCOR
Blucora
$32.06
+1.0%
$25.54
$15.10
$27.75
$1.54B1.25313,650 shs136 shs
BMED
iShares Health Innovation Active ETF
$26.05
+0.1%
$25.08
$20.57
$27.02
$4.17M0.771,824 shs258 shs
CLIA
Veridien Climate Action ETF
$18.61
-0.2%
$18.61
$16.48
$21.28
$23.45M1.349,925 shs75,500 shs
THNR
Amplify Weight Loss Drug & Treatment ETF
$22.82
-0.4%
$22.84
$18.56
$28.19
$2.97MN/A2,059 shs538 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Blucora, Inc. stock logo
BCOR
Blucora
-1.20%-0.81%-6.79%+2.67%+16.74%
BMED
iShares Health Innovation Active ETF
+0.50%+0.70%+1.96%+9.19%-0.95%
CLIA
Veridien Climate Action ETF
0.00%0.00%0.00%0.00%0.00%
THNR
Amplify Weight Loss Drug & Treatment ETF
+0.17%+0.48%-3.94%+5.00%-17.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Blucora, Inc. stock logo
BCOR
Blucora
N/AN/AN/AN/AN/AN/AN/AN/A
BMED
iShares Health Innovation Active ETF
N/AN/AN/AN/AN/AN/AN/AN/A
CLIA
Veridien Climate Action ETF
N/AN/AN/AN/AN/AN/AN/AN/A
THNR
Amplify Weight Loss Drug & Treatment ETF
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Blucora, Inc. stock logo
BCOR
Blucora
0.00
N/AN/AN/A
BMED
iShares Health Innovation Active ETF
2.77
Moderate Buy$26.05N/A
CLIA
Veridien Climate Action ETF
2.50
Hold$18.61N/A
THNR
Amplify Weight Loss Drug & Treatment ETF
2.58
Moderate Buy$22.82N/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Blucora, Inc. stock logo
BCOR
Blucora
$885.20M1.74$2.83 per share11.33$7.01 per share4.57
BMED
iShares Health Innovation Active ETF
N/AN/AN/AN/AN/AN/A
CLIA
Veridien Climate Action ETF
N/AN/AN/AN/AN/AN/A
THNR
Amplify Weight Loss Drug & Treatment ETF
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Blucora, Inc. stock logo
BCOR
Blucora
$7.76M$0.5657.2414.250.813.12%15.60%5.29%N/A
BMED
iShares Health Innovation Active ETF
N/AN/A24.91N/AN/AN/AN/AN/A
CLIA
Veridien Climate Action ETF
N/AN/A16.68N/AN/AN/AN/AN/A
THNR
Amplify Weight Loss Drug & Treatment ETF
N/AN/A24.31N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Blucora, Inc. stock logo
BCOR
Blucora
N/AN/AN/AN/AN/A
BMED
iShares Health Innovation Active ETF
N/AN/AN/AN/AN/A
CLIA
Veridien Climate Action ETF
N/AN/AN/AN/AN/A
THNR
Amplify Weight Loss Drug & Treatment ETF
$0.220.96%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Blucora, Inc. stock logo
BCOR
Blucora
1.40
2.51
2.51
BMED
iShares Health Innovation Active ETF
N/AN/AN/A
CLIA
Veridien Climate Action ETF
N/AN/AN/A
THNR
Amplify Weight Loss Drug & Treatment ETF
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Blucora, Inc. stock logo
BCOR
Blucora
1,10048.14 million47.01 millionNo Data
BMED
iShares Health Innovation Active ETF
N/A160,000N/ANot Optionable
CLIA
Veridien Climate Action ETF
N/A1.26 millionN/ANot Optionable
THNR
Amplify Weight Loss Drug & Treatment ETF
N/A130,000N/AN/A

Media Sentiment Over Time

Blucora stock logo

Blucora NASDAQ:BCOR

Avantax, Inc. engages in the provision of integrated tax-focused wealth management services and software. It operates through the Wealth Management and Tax Preparation segments. The Wealth Management segment consists of the operations of Avantax, which provides tax-focused wealth management solutions for financial advisors, tax preparers, certified public accounting firms, and its clients. The Tax Preparation segment focuses on digital tax preparation solutions for consumers, small business owners, and tax professionals. The company was founded by Naveen Mahendra Kumar Jain in March 1996 and is headquartered in Dallas, TX.

iShares Health Innovation Active ETF NYSEARCA:BMED

$26.04 +0.02 (+0.06%)
As of 01:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

The BlackRock Future Health ETF (BMED) is an exchange-traded fund that is based on the MSCI All Country World index. The fund is actively managed to invest in global equities in the health sciences industry. BMED was launched on Sep 29, 2020 and is managed by BlackRock.

Veridien Climate Action ETF NYSEARCA:CLIA

$18.61 -0.04 (-0.21%)
As of 08/16/2024

The Veridien Climate Action ETF (CLIA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed, non-transparent ETF that seeks to invest in companies, via US-listed stocks or ADRs from around the world, that are considered to be making a substantial contribution to mitigating climate change. The fund utilizes the Precidian non-transparent model CLIA was launched on May 8, 2023 and is managed by Veridien.

Amplify Weight Loss Drug & Treatment ETF NYSEARCA:THNR

$22.82 -0.09 (-0.41%)
As of 03:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.